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In the past few years, tumour budding at the invasive margin has been reported as a new risk factor for lymph node metastasis in
advanced colorectal cancers, but it is sometimes difficult to detect tumour budding in submucosal colorectal cancer by haematoxylin
and eosin staining. We immunohistochemically examined tumour budding at the deepest invasive margin of 56 surgically resected
submucosal colorectal carcinomas using anticytokeratin antibody CAM5.2, furthermore checked by AE1/AE3, and determined the
relation between tumour budding and clinicopathological factors. Moreover, we used the monoclonal antibody D2-40 for
immunohistochemistry to detect lymphatic involvement. Tumour budding was detected in 42 cases (75.0%), and the budding-
positive group showed a significantly higher rate of lymph node metastasis (including isolated tumour cells) (16/42 vs 0/14; P¼0.004)
than the budding-negative group. The sensitivity and negative predictive value of tumour budding alone for lymph node metastasis
were superior to those of lymphatic invasion alone. Furthermore, the specificity and positive predictive value of the combination of
either lymphatic invasion or tumour budding were superior to those of lymphatic invasion alone. Tumour budding detected
immunohistochemically by using CAM5.2 is a newly found risk factor for lymph node metastasis and may help to avoid oversurgery in
the future.
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Recently, endoscopic polypectomy or endoscopical mucosal
resection has been performed extensively for the treatment of
colorectal adenomas, and intramucosal and submucosal carcino-
mas (Williams et al, 2000; Kudo et al, 2001; Tung et al, 2001).
However, it has been reported that lymph node metastasis is
present in about 10% of submucosal carcinomas (Wilcox et al,
1986; Muto et al, 1991). Therefore, if the polypectomised specimen
is revealed to be a submucosal carcinoma, additional surgical
resection of the colon or rectum with lymph node dissection is
recommended. However, if additional surgery is performed for all
submucosal carcinomas after endoscopical resection, only 10% of
patients benefit from dissecting surgery for lymph node meta-
stasis. In other words, about 90% of the patients undergo
unnecessary surgery, since these patients do not have any lymph
node metastasis. If the presence of lymph node metastasis can be
accurately predicted from the polypectomised specimen, over-
surgery can be avoided. In order to select those patients who are at
a high risk for lymph node metastasis, lymphatic involvement has
been considered a risk factor in polypectomised submucosal
carcinoma (Morson et al, 1977; Haggitt et al, 1985; Muto et al,
1991). However, it is difficult to identify a lymphatic involvement
by cancer cells with routine haematoxylin and eosin (H.E) staining
and both the sensitivity and the positive predictive value of this
risk factor for lymph node metastasis remain low. Studies of
advanced colorectal cancers have recently demonstrated that
tumour budding at the invasive margin is a risk factor for lymph
node metastasis (Morodomi et al, 1989; Hase et al, 1993; Ono et al,
1996; Goldstein and Hart, 1999; Okuyama et al, 2002; Ueno et al,
2002; Tanaka et al, 2003; Park et al, 2005). However, so far there
have been few studies that have examined tumour budding in
submucosal carcinomas with respect to lymph node metastasis
(Makino et al, 2000; Masaki et al, 2001b; Ueno et al, 2004).
Pathologically tumour budding is defined as a single cell or a
small cluster of cells away from the tumour mass. It is sometimes
difficult, therefore, to detect tumour budding by examining
the polypectomised specimen with H.E alone. Cytokeratin is a
component of the cytoskeleton of the epithelial cells that is not
present in the normal submucosal layer and normal lymph nodes.
Therefore, in the present study, we used not only H.E but also
immunohistochemical staining CAM5.2, furthermore checked by
AE1/AE3, to make a more accurate diagnosis of tumour budding
and D2-40 to detect lymphatic involvement. It has recently been
reported that CAM5.2 antibody is useful for detecting lymph
node micrometastasis or isolated tumour cells (ITCs) in various
gastrointestinal and biliary cancers (Oberg et al, 1998; Cai et al,
1999; Yokoyama et al, 1999; Yasuda et al, 2002; Tojima et al, 2003).
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sTherefore, we also examined the lymph node metastasis
(including micrometastasis and ITCs) of submucosal cancer using
CAM5.2. The monoclonal antibody D2-40, which has been
developed against a testicular oncofetal antigen, has been
demonstrated to recognise lymphatic vessels in the breast, colonic
carcinoma and head and neck squamous cell carcinoma (Marks
et al, 1999; Kahn and Marks, 2002; Fogt et al, 2004; Franchi et al,
2004).
The aim of the present study is to examine whether tumour
budding could be a newly found risk factor for lymph node
metastasis in submucosal carcinoma. Furthermore, we examined
the relation between tumour budding and lymph node micro-
metastasis and ITCs by using CAM5.2. To the best of our
knowledge, this is the first study that has examined tumour
budding in submucosal colorectal carcinoma by CAM5.2 immuno-
histochemistry with respect to lymph node metastasis.
MATERIALS AND METHODS
Specimens
We examined 56 surgically resected submucosal colorectal
adenocarcinomas from the surgical pathology files of the Depart-
ment of Surgical Oncology, The University of Tokyo, Tokyo, Japan
from March 1990 to June 2001. The resected specimens were
immediately fixed in 10% buffered formalin and the entire
tumours were cut into step-wise sections and embedded in
paraffin. Pathological diagnoses of the primary lesions were made
by H.E, and the presence of venous and lymphatic permeation was
assessed in greater detail by the methods described below. In order
to confirm the deepest points of invasion and the presence of
venous and lymphatic permeation, one to 17 step-wise sections
were cut from each primary tumour.
Histological examination
Two 3-mm-thick sections for CAM5.2 (Becton Dickinson, San Jose,
CA, USA) (diluted 1:3) and AE1/AE3 (Dako, Kyoto, Japan)
(diluted 1:150) immunostaining were cut from the deepest
invasive specimen in order to examine the budding at the deepest
invasive margin (Figure 1).
For the examination of venous and lymphatic permeation, three
3-mm-thick sections were prepared. The first of the three 3mm
sections was used for H.E, the next for Victoria blue elastic fibre
staining to visualise the elastic fibres of the venous wall and the last
was used for immunostaining with anti-human lymphatic endo-
thelial cell D2-40 (Signet, Dedham, MA, USA) (diluted 1:100) to
visualise the endothelial cells of the lymphatic channels
(Figure 2A).
Lymph nodes
Lymph nodes were routinely examined by one section through the
centre of each lymph node. Two experienced pathologists
independently examined all sections and confirmed the absence
of visible metastatic deposit in all lymph nodes. A total of 628
lymph nodes were dissected from the 56 patients. The average
number of lymph nodes dissected per patient was 11.2 (range,
1–60 nodes). For micrometastasis and ITCs analysis, we examined
three serial sections, each 10mm thick (with an aggregate thickness
of 30mm), from each of the paraffin blocks of the lymph nodes,
which were used for CAM5.2 immunohistochemical examination
as described below (Figure 2B).
D2-40, CAM5.2 and AE1/AE3 immunohistochemical
staining
The streptavidin–biotin (SAB) immunoperoxidase method was
used. For D2-40 staining, the sections were deparaffinised with
xylene and dehydrated with 98% ethanol, placed in 0.01 M sodium
citrate buffer (pH 6.0), and heated in a microwave oven for three
7-min cycles (500W). After washing twice in phospahte-buffered
saline (PBS), endogenous peroxidase activity was inhibited by
incubation with 0.3% hydrogen peroxide in methanol for 20min.
After three washes in PBS, nonspecific reaction was blocked by
incubation at room temperature. Reagents for the subsequent step,
biotinylated rabbit anti-mouse immunogloblin and SAB complex,
supplied commercially (Histfine SAB-PO(M) kit, Nichirei, Tokyo,
Japan) were used. The sections were incubated with anti-D2-40
Figure 1 (A) Immunohistochemical staining of tumour budding using an anticytokeratin antibody, CAM5.2 (original magnification,  50). (B) Tumour
budding at the invasive margin, using H.E (original magnification,  50). (C) Immunohistochemical staining of a case without tumour budding using an
anticytokeratin antibody, CAM5.2 (original magnification,  10). (D) A case without tumour budding at the invasive margin, using H.E (original magnification,
 10).
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diaminobenzidine solution. The sections were then lightly counter-
stained with a cocktail of Mayer’s/Lillie–Mayer’s haematoxylin
and mounted. For CAM5.2 and AE1/AE3 staining, the sections
were deparaffinised with xylene and dehydrated with 98% ethanol,
and treated with 0.1% trypsin (Sigma Chemical Company, St Louis,
MO, USA) in 0.1% calcium chloride (pH 7.8) at 371C for 20min
before immunostaining; they were treated in the same way as with
D2-40 staining, and counterstained with methyl green and
mounted.
Definition of tumour budding
Tumour budding refers to microscopic microtubular cancer nests
and undifferentiated cancer cells at the invasive margin of the
carcinomatous lesion, as proposed by Morodomi et al (1989) and
Hase et al (1993). In this study, we examined this tumour budding
by specimens stained by CAM5.2 immunohistochemistry, and
checked by AE1/AE3 immunohistochemistry, because single
tumour cells are more easily detected by staining with CAM5.2
than with H.E. Cases with budding were classified as the budding-
positive group, and cases without budding as the budding-negative
group.
Definition of lymph node metastasis
Tumour deposits within lymph nodes were classified according to
the revised guidelines set by American Committee on Cancer
(AJCC) (Hermanek et al, 1999). The lymph nodes were classified as
pN0, pN1 and pN2 according to the current AJCC criteria for
colorectal cancer. Isolated tumour cells were single tumour cells or
cell clusters that measured no greater than 0.2mm and were
detected by H.E and/or immunohistochemistry (pN0i  and
pN0iþ). Isolated tumour cells were included in the category of
lymph node metastasis. Micrometastasis was diagnosed when the
tumour nodule in the lymph node was smaller than 2mm in
diameter (pN1mi and pN2mi). Although reticular cells and plasma
cells in lymph nodes can show staining for CAM5.2, these non-
neoplastic cells were easily discriminated from ITCs by differing
staining patterns, as described by Sasaki et al (1998).
Statistical analysis
All statistical calculations were carried out with StatView-J 5.0
statistical software (SAS Institute, Cary, NC, USA). w
2 test and
Student’s t-test were used to analyse data. A P-value o0.05 was
considered to indicate statistical significance.
RESULTS
Clinicopathological features in submucosal colorectal
carcinomas
The characteristics of the 56 tumours are shown in Table 1. Among
seven cases with lymphatic involvement, six were diagnosed by
Figure 2 (A) Lymphatic involvement by immunostaining with anti-
human lymphatic endothelial cell D2-40 (original magnification,  50). (B)
Isolated tumour cells from colorectal carcinoma in a lymph node.
Immunohistochemical staining using an anticytokeratin antibody, CAM5.2
(original magnification,  50).
Table 1 Clinicopathological features in submucosal colorectal cancers
Gender
Male 41 (73.2%)
Female 15 (26.8%)
Mean age (years)7s.d. 62.8710.5
Size (mm)7s.d. 22.8710.5
Location
Caecum 1 (1.8%)
Ascending colon 7 (12.5%)
Transverse colon 7 (12.5%)
Descending colon 3 (5.4%)
Sigmoid colon 24 (42.9%)
Rectum 14 (25.0%)
Gross appearance
Polypoid 33 (58.9%)
Flat or depressed 23 (41.1%)
Histologic type
Well 47 (83.9%)
Moderately 8 (14.3%)
Poorly
a 1 (1.8%)
Lymphatic involvement (H.E and D2-40 immunohistochemistry)
Absent 49 (87.5%)
Present 7 (12.5%)
Venous involvement (H.E and Victoria blue staining)
Absent 25 (44.6%)
Present 31 (55.4%)
Lymph nodes metastasis
pN0 40 (71.4%)
ITCs (pN0i( ) and pN0i(+)) 8 (14.3%)
pN1mi 3 (5.4%)
pN1 5 (8.9%)
H.E¼haematoxylin and eosin staining; ITC¼isolated tumour cells; s.d.¼standard
deviation.
aThe histologic type of poorly differentiated adenocarcinoma was
medullary.
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H.E. Among 31 cases with venous involvement, 20 were diagnosed
by H.E and 11 by Victoria blue elastic fibre staining; the latter cases
were not detected by H.E. Isolated tumour cells were detected in
eight cases (14.3%), with the aid of immunohistochemistry
(pN0i(þ)) in seven cases and the aid of H.E (pN0i( )) in one
case. The lymph node from three of eight patients with pN1 nodal
status at initial examination had metastasis measuring from
0.2mm in diameter up to a maximum of 2mm and could be
reclassified as pN1mi. None of the pN1 patients were upstaged to
pN2 as a result of encountering ITCs.
Tumour budding in submucosal colorectal cancers
Tumour budding was detected in 42 cases (75.0%) by CAM5.2
immunohistochemistry, and all cases detected by CAM5.2 were
also positive for AE1/AE3 immunohistochemistry. No case with
tumour budding was newly detected by AE1/AE3 immunohisto-
chemistry. Table 2 shows the correlation between tumour budding
in the primary tumours of submucosal colorectal cancers and their
clinicopathological features. The budding-positive group showed a
significantly higher rate of lymph node metastasis (16/42 vs 0/14;
P¼0.004) than the budding-negative group. Moreover, the former
group showed a higher rate of lymphatic involvement (7/42 vs 0/
14; P¼0.12) than the latter group, but not significantly. All 14
cases without tumour budding showed no lymphatic involvement
or lymph node metastasis. There was no relation between tumour
budding and venous involvement.
Sensitivity, specificity and predictive value of lymphatic
invasion and tumour budding for lymph node metastasis
The sensitivity, specificity and predictive value of lymphatic
invasion, tumour budding and the combination of these two
factors for lymph node metastasis are shown in Table 3.
Sensitivity, specificity, positive predictive value and negative
predictive value of lymphatic invasion alone for lymph node
metastasis were 37.5, 97.5, 85.7 and 79.6%, respectively, whereas
those of tumour budding alone (the combination of either
lymphatic invasion or tumour budding) were 100, 65, 38.1 and
100% (43.7, 100, 100 and 81.6%), respectively.
DISCUSSION
We were able to show that tumour budding is a newly discovered
risk factor for lymph node metastasis in submucosal colorectal
carcinoma. There is, therefore, a possibility that oversurgery for
polypectomised submucosal colorectal carcinoma can be avoided
by examining tumour budding.
Tumour budding is defined as anaplastic thin cell cords or
individual free cells, microtubular cancer nests or undifferentiated
cancer cells (Morodomi et al, 1989). This histological appearance
is also expressed by various terms such as ‘sprouting’, ‘focal
dedifferentiation’ and ‘budding’ (Morodomi et al, 1989; Ono et al,
1996). Tumour budding was first reported by Imai. Although he
used the term ‘sprouting’ instead of ‘budding’, he showed that
Table 2 Tumour budding in submucosal colorectal cancers and
clinicopathological features
Tumour budding
n Present Absent P-value
Mean age (years)7s.d. 56 61.8711.0 65.978.0 NS
Gender
Male 41 31 10 NS
Female 15 11 4
Size (mm)7s.d. 56 21.779.3 25.9716.6 NS
Histologic type
Well 47 35 12 NS
Moderately 8 7 1
Poorly 1 0 1
Lymphatic involvement
Absent 49 35 14 0.12
Present 7 7 0
Lymph nodes metastasis (including ITCs and micrometastasis)
Absent 40 26 14 0.004
Present 16 16 0
Venous involvement
Absent 25 20 5 NS
Present 31 22 9
ITC¼isolated tumour cells; NS¼not significant; s.d.¼standard deviation.
Table 3 Predictive value of tumour budding, lymphatic invasion and combination of budding and lymphatic invasion for lymph nodes metastasis
Lymph node metastasis (including
ITCs and micrometastasis)
Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%) Present Absent
Lymphatic invasion
Present 6 1 37.5 97.5 85.7 79.6
Absent 10 39
Tumour budding
Present 16 26 100.0 65.0 38.1 100.0
Absent 0 14
Lymphatic invasion or tumour budding
Present 16 26 100.0 65.0 38.1 100.0
Absent 0 14
Lymphatic invasion and tumour budding
Present 7 0 43.7 100.0 100.0 81.6
Absent 9 40
ITC¼isolated tumour cells.
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stumour with sprouting, regardless of the presence or absence of
peritumour stromal invasion, have higher malignant potential in
various cancers. Morodomi et al (1989) showed that tumour
budding strongly correlated with lymphatic invasion and lymph
node metastasis in rectal cancers. Hase et al (1993) reported that
tumour budding was an important predictor for recurrence and
poor prognosis in patients with colorectal cancers. Furthermore,
some oncologists and pathologists showed that tumour budding
was significantly associated with lymph node metastasis, local
recurrence, distant metastasis and poor prognosis in advanced
colorectal cancers (Ono et al, 1996; Goldstein and Hart, 1999;
Okuyama et al, 2002; Ueno et al, 2002).
In previous reports, tumour budding was detected by using H.E
specimens. However, considering that tumour budding is very
small in size, since they are small cluster of cells or sometimes even
a single cell away from the tumour mass, it is sometimes difficult
to detect tumour budding by conventional pathological examina-
tion of the polypectomised specimen using this method. Therefore,
in the present study, in addition to H.E, we examined tumour
budding by not only CAM5.2 but also AE1/AE3 immunohisto-
chemistry, which makes it much easier to detect a small number of
cells. CAM5.2 is an antibody against cytokeratins 8 and 18, and
AE1/AE3 is an antibody against cytokeratins 1–8, 10, 14–16 and
19, which are components of the cytoskeleton of the epithelial cells
(Moll et al, 1982). CAM5.2 has been used to detect minute deposits
of tumour cells. Recent studies have demonstrated the high
sensitivity, high accuracy and cost effectiveness of this immuno-
histochemical method using CAM5.2 to detect lymph node
micrometastasis or ITCs in various tumours originating from the
stomach (Cai et al, 1999), colorectum (Oberg et al, 1998; Yasuda
et al, 2002), gall bladder (Yokoyama et al, 1999) or bile duct
(Tojima et al, 2003). Moreover, studies of lymph node ITCs in
colorectal cancer by using CAM5.2 have shown that ITCs
correlated significantly with poor prognosis (Haboubi et al, 1992;
Isaka et al, 1999; Yasuda et al, 2002). Therefore, in the present
study, we also examined ITCs in the lymph nodes with respect to
tumour budding, using CAM5.2. To the best of our knowledge, this
is the first report to demonstrate the relation between tumour
budding and lymph node metastasis including ITCs in submucosal
colorectal carcinoma by using CAM5.2 immunohistochemistry. At
the present time, the main risk factor for lymph node metastasis in
submucosal colorectal carcinoma is thought to be the presence of
lymphatic involvement (Morson et al, 1977; Haggitt et al, 1985;
Muto et al, 1991). However, the identification of lymphatic
involvement by cancer cells on routine H.E has been difficult. In
this study, we used the monoclonal antibody D2-40 to visualise the
endothelium of lymphatic channel. However, in using this risk
factor, sensitivity and positive predictive values of lymph node
metastasis are low. In the present study, the sensitivity and
negative predictive value of tumour budding alone were superior
to those of lymphatic invasion alone, but the specificity and
positive predictive value of tumour budding alone were not
superior to those of lymphatic invasion alone. However, when both
of these factors were combined, sensitivity and positive predictive
value were not only 100%, but superior to those of lymphatic
invasion alone. Furthermore, we were able to show that all cases
without budding at the deepest invasive margin have no lymphatic
invasion or lymph node metastasis. By defining the risk factor of
lymph node metastasis as positive when either lymphatic invasion
or tumour budding is present, we were able to demonstrate for the
first time that all sensitivity, specificity, positive and negative
predictive values for lymph node metastasis were superior to those
of lymphatic invasion alone. These results show that tumour
budding combined with lymphatic invasion is of great use as a risk
factor for lymph node metastasis in polypectomised submucosal
carcinoma. The higher negative predictive value of budding than
that of lymphatic involvement is useful in clinical practice. The
indicator for colectomy with lymph node dissection for previously
polypectomised cancer may be determined based on budding. If
the polypectomised specimen has no budding, additional colect-
omy, therefore, may not be indicated. Moreover, the higher
positive predictive value of budding and lymphatic involvement
than that of lymphatic involvement is useful, too. The combination
of budding and lymphatic involvement may provide information
useful for postoperative follow-up and for determining the need
for adjuvant chemotherapy, even if the case was submucosal
cancer.
In the past few years, important molecular events concerning
with tumour budding, such as the gain and loss of adhesion
molecules, secretion of proteolytic enzymes, reduction of tumour
proliferation and mutation of tumour suppressor genes, have been
examined. Sordat et al (2000) reported that budding cells in
colorectal carcinomas underexpress the laminin-5 a3-subunit,
while retaining expression of the b3- and g2-subunits. Masaki et al
(2001a, 2003) suggested that expression of the laminin-5 g2-chain
with or without matrilysin (MMP-7), or upregulation of CD44
variant 6 through nuclear b-catenin activation contributed to the
formation of budding cell at the invasive front. Guzinska et al
(2004) reported the activity of cathepsin B, which connect with
proteolytic effect on basement membrane and intestinal stroma
and has promotion role in carcinogenesis, correlated with tumour
budding. Jung et al (2001) showed that tumour budding was
associated with reduced proliferation, but with nuclear cyclin D1
expression. Moreover, Makino et al (2000) showed that tumour
budding was significantly more frequent in p53-positive than p53-
negative tumours, and Jass et al (2003) reported that the frequency
of both budding and APC mutation was higher than that in
microsatellite instability (MSI) high, hereditary nonpolyposis
colorectal cancer, MSI low and MSI stable. They also emphasised
that these findings indicate that tumour budding is a dynamic
process under genetic control and not merely the result of
architectural disruption caused by a host immune reaction at the
tumour margin (Jass et al, 2003). The correlation between tumour
budding and various molecular events may be helpful in our future
understanding of the malignant potential of tumour budding in
colorectal cancer, although more biological research is needed.
In conclusion, our results indicate that tumour budding
correlates with lymph node metastasis in submucosal colorectal
cancers, and that this parameter is a useful indicator of the risk of
lymph node metastasis in such cancers. Detection of tumour
budding by CAM5.2 immunohistochemistry may help to avoid
oversurgery in the future. A new study with a larger number of
cases, especially in a prospective and multicenter setting, is
necessary.
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